Program
chiglitazar
Also written as “Chiglitazar”, “Chiglitazar/Metformin extended-release tablets under fasting conditions” and “Chiglitazar/Metformin extended-release tablets after a high-fat meal”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, led by Chipscreen Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciences | 90 open or running | phase 3since Apr 22, 2014 | Apr 22, 2014 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2014First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT02121717 · 535 enrolled · China
- Jun 20, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02173457 · 740 enrolled · China
- Mar 17, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04807348 · 533 enrolled · China
- Dec 3, 2021Phase 2 study in NASHNCT05193916 · 104 enrolled · China
- Aug 23, 20222 phase 1 studiesNCT05515458, NCT05515445
- Dec 27, 2022Phase 1 study in T2DMNCT05681273 · 48 enrolled · China
- Mar 20, 2026No phase study in Diabetes Mellitus, Type 2NCT07519265 · 64 enrolled · China
- Mar 20, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07511010 · 28 enrolled · China
TargetBeta
“Peroxisome proliferator-activated receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07519265Diabetes Mellitus, Type 2 · China | – | Completed | Aug 3, 2026 | 64 |
| NCT07511010Diabetes Mellitus, Type 2 · China | 1 | Completed | Oct 22, 2026 | 28 |
| NCT05681273T2DM · China | 1 | Completed | Mar 21, 2023 | 48 |
| NCT05515458Renal Insufficiency · China | 1 | Completed | Jul 19, 2023 | 24 |
| NCT05515445Hepatic Impairment · China | 1 | Completed | Aug 23, 2023 | 24 |
| NCT05193916NASH · China | 2 | Completed | Jan 2, 2024 | 104 |
| NCT04807348Diabetes Mellitus, Type 2 · China | 3 | Completed | Feb 10, 2023 | 533 |
| NCT02173457Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 2017 | 740 |
| NCT02121717Diabetes Mellitus, Type 2 · China | 3 | Completed | Nov 2017 | 535 |
How it is read
Names in the registry
- “Chiglitazar”, 5 entries
- “Chiglitazar/Metformin extended-release tablets under fasting conditions”, 1 entry
- “Chiglitazar/Metformin extended-release tablets after a high-fat meal”, 1 entry
- “multiple-dose of Chiglitazar/Metformin extended-release tablets”, 1 entry
- “Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 5 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.